Last reviewed · How we verify

Aripiprazole Augmentation — Competitive Intelligence Brief

Aripiprazole Augmentation (Aripiprazole Augmentation) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic / dopamine partial agonist. Area: Psychiatry / Mental Health.

marketed Atypical antipsychotic / dopamine partial agonist D2 dopamine receptor, 5-HT1A serotonin receptor Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Aripiprazole Augmentation (Aripiprazole Augmentation) — Centre for Addiction and Mental Health. Aripiprazole augmentation enhances the efficacy of antidepressants by acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, improving mood regulation in treatment-resistant depression.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aripiprazole Augmentation TARGET Aripiprazole Augmentation Centre for Addiction and Mental Health marketed Atypical antipsychotic / dopamine partial agonist D2 dopamine receptor, 5-HT1A serotonin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic / dopamine partial agonist class)

  1. Centre for Addiction and Mental Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aripiprazole Augmentation — Competitive Intelligence Brief. https://druglandscape.com/ci/aripiprazole-augmentation. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: